trastuzumab deruxtecan

targets

all catalysts(13)

News(10)

• STAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal
  A breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of the U.S.-U.K. pharma pact.
  stat · 17d ago
• WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
  The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
  biopharma_dive · 19d ago
• Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
  Plus news about Lilly, Cellectis, Tyra, Shennon and QL Biopharm. Electra Therapeutics eyes $297M IPO: The Sanofi-backed biotech hopes to kick off the post-Labor Day IPO train with a nearly $300 mil…
  endpoints · 20d ago
• Unlocking cell surface protein research with site-specific labeling
  Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
  biospace · 21d ago
• Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
  Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with the modality. Th…
  fiercebiotech · 1mo ago
• Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
  Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
  biospace · 1mo ago
• AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
  AstraZeneca on Monday reported successes in two late-stage trials in different forms of lung cancer — one with a two-drug combination of Tagrisso and Orpathys and another with its blockbuster antib…
  endpoints · 1mo ago
• ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
  If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
  biospace · 2mo ago
• Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
  With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
  biospace · 2mo ago
• AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
  AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
  fiercebiotech · 2mo ago